DelMar Pharmaceuticals, Inc. Sample Contracts

COMMON STOCK PURCHASE WARRANT KINTARA THERAPEUTICS, INC.
Common Stock Purchase Warrant • April 13th, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 14, 2022 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on April 14, 2027 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Sample 1Sample 2Sample 3See All (1k)
AutoNDA by SimpleDocs
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • April 13th, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of April 12, 2022, between Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Sample 1Sample 2Sample 3See All (1k)
SECURITIES PURCHASE AGREEMENT
Securities Purchase Agreement • June 3rd, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This Securities Purchase Agreement (this “Agreement”) is dated as of June 3, 2019, between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).

Sample 1Sample 2Sample 3See All (828)
PLACEMENT AGENT WARRANT TO PURCHASE SHARES OF COMMON STOCK KINTARA THERAPEUTICS, INC.
Warrant Agreement • October 24th, 2023 • Kintara Therapeutics, Inc. • Pharmaceutical preparations

THIS WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on [*], 2028 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Placement Agent Agreement, dated as of [*], 2023 by and between the Company and A.G.P./Alliance Global Partners.

Sample 1Sample 2Sample 3See All (505)
PRE-FUNDED COMMON STOCK PURCHASE WARRANT
Pre-Funded Common Stock Purchase Warrant • September 28th, 2021 • Kintara Therapeutics, Inc. • Pharmaceutical preparations

THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Sample 1Sample 2Sample 3See All (439)
COMMON STOCK PURCHASE WARRANT
Common Stock Purchase Warrant • September 28th, 2021 • Kintara Therapeutics, Inc. • Pharmaceutical preparations

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after September 28, 2021 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on March 28, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Sample 1Sample 2Sample 3See All (399)
DELMAR PHARMACEUTICALS, INC and MOUNTAIN SHARE Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August [ ], 2019
Warrant Agency Agreement • August 12th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

WARRANT AGENCY AGREEMENT, dated as of August [ ], 2019 (“Agreement”), between DelMar Pharmaceuticals, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and Mountain Share Transfer, LLC (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (272)
SHARES of Common Stock, _________ PRE-FUNDED warrants (exercisable for _________ Shares) and _________ Warrants (exercisable for _________ Shares) of DELMAR PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • August 12th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

The undersigned, DelMar Pharmaceuticals, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of DelMar Pharmaceuticals, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representatives (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC and Dawson James Securities, Inc. are acting as representatives to the several Underwriters (each a “Representative” and collectively, the “Representatives” and if there are no Underwriters other than the Representatives, references to multiple Underwriters shall be disregarded and the term Representatives as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

Sample 1Sample 2Sample 3See All (229)
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT kintara therapeutics, inc.
Placement Agent Common Stock Purchase Warrant • April 13th, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations

THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after October 14, 2022 (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on October 14, 2026 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Placement Agent Agreement, dated as of April 12, 2022 by and between the Company and A.G.P./Alliance Global Partners.

Sample 1Sample 2Sample 3See All (171)
PURCHASE AGREEMENT
Purchase Agreement • August 3rd, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Nevada

PURCHASE AGREEMENT (the “Agreement”), dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation (the “Company”), LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).

Sample 1Sample 2Sample 3See All (171)
Kintara Therapeutics, Inc.
Placement Agent Agreement • April 13th, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
Sample 1Sample 2Sample 3See All (123)
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.
Common Stock Purchase Warrant • June 23rd, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Initial Exercise Date (as set forth above) and on or prior to the close of business on the [____] year anniversary of the Issue Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Sample 1Sample 2Sample 3See All (121)
WARRANT AGENT AGREEMENT
Warrant Agent Agreement • May 12th, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This Warrant Agent Agreement made as of May __, 2015, is between DelMar Pharmaceuticals, Inc. a Nevada corporation, with offices at 720-999 West Broadway, Vancouver, British Columbia, Canada V5Z1K5 (the “Company”), and Island Stock Transfer with offices at 15500 Roosevelt Blvd, Suite 301, Clearwater Florida 33760 (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (119)
DELMAR PHARMACEUTICALS, INC and MOUNTAIN SHARE Transfer, LLC, as Warrant Agent Warrant Agency Agreement Dated as of August 14, 2019
Warrant Agency Agreement • August 15th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

WARRANT AGENCY AGREEMENT, dated as of August 14, 2019 (“Agreement”), between DelMar Pharmaceuticals, Inc., a corporation organized under the laws of the State of Nevada (the “Company”), and Mountain Share Transfer, LLC (the “Warrant Agent”).

Sample 1Sample 2Sample 3See All (92)
STRICTLY CONFIDENTIAL Jeffrey Bacha Chairman & CEO DelMar Pharmaceuticals, Inc. Suite 720 - 999 West Broadway Vancouver, British Columbia Canada V5Z 1K5 Dear Mr. Bacha:
Exclusive Agency Agreement • September 21st, 2017 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This letter agreement (this “Agreement”) constitutes the agreement between DelMar Pharmaceuticals, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”) that Wainwright shall serve as the exclusive agent, advisor or underwriter in an offering (the “Offering”) of securities of the Company (“Securities”) during the Term (as defined below) of this Agreement. The terms of the Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in the Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwright in connectio

Sample 1Sample 2Sample 3See All (92)
BERRY ONLY INC.
Private Placement Subscription Agreement • September 14th, 2012 • Berry Only Inc. • Specialty cleaning, polishing and sanitation preparations • Nevada
Sample 1Sample 2Sample 3See All (83)
Kintara Therapeutics, Inc. COMMON STOCK SALES AGREEMENT
Sales Agreement • September 19th, 2023 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York
Sample 1Sample 2Sample 3See All (81)
DELMAR PHARMACEUTICALS, INC. DEALER-MANAGER AGREEMENT
Dealer-Manager Agreement • June 10th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
Sample 1Sample 2Sample 3See All (59)
INDEMNITY AGREEMENT
Indemnification Agreement • October 21st, 2024 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Nevada

This Indemnity Agreement (this “Agreement”) dated as of ___________ _____, _____, is made by and between TuHURA Biosciences, Inc., a Nevada corporation (the “Company”), and _________________ (“Indemnitee”).

Sample 1Sample 2Sample 3See All (49)
Saiid Zarrabian President and Chief Executive Officer DelMar Pharmaceuticals, Inc. Suite 720-999 West Broadway Vancouver, British Columbia, Canada V5Z 1K5 Dear Mr. Zarrabian:
Placement Agent Agreement • June 3rd, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This letter (the “Agreement”) constitutes the agreement between Maxim Group LLC (“Maxim”), Dawson James Securities, Inc. (“DJ” and together with Maxim, the “Placement Agents”) and Delmar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), pursuant to which the Placement Agents shall serve as the placement agents for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of common stock (the “Shares”) of the Company, par value $0.001 per share (“Common Stock”), warrants to purchase Common Stock (the “Warrants” and, collectively with the Shares, the “Securities”). The terms of the Placement and the Securities shall be mutually agreed upon by the Company and the purchasers (each, a “Purchaser” and collectively, the “Purchasers”) and nothing herein constitutes that the Placement Agents would have the power or authority to bind the Company or any Purchaser or an obligation for the Company to issue any Securities or complete th

Sample 1Sample 2Sample 3See All (47)
EMPLOYMENT AGREEMENT
Employment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey

This EMPLOYMENT AGREEMENT (this “Agreement”), dated April 8, 2016 and effective on the date of consummation of the initial closing of the private placement offering of the Company’s common stock (the “Effective Date”), is by and between ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”) and Steven J. Rychnovsky (the “Executive”).

Sample 1Sample 2Sample 3See All (35)
PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK KINTARA THERAPEUTICS, INC.
Pre-Funded Warrant Agreement • October 24th, 2023 • Kintara Therapeutics, Inc. • Pharmaceutical preparations

THIS PRE-FUNDED WARRANT TO PURCHASE SHARES OF COMMON STOCK (this “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), up to ______ shares of Common Stock, par value $0.001 per share (the “Common Stock”), of the Company (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Sample 1Sample 2Sample 3See All (34)
AutoNDA by SimpleDocs
Contract
Placement Agency Agreement • October 24th, 2023 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York

Subject to the terms and conditions of this letter agreement (the “Agreement”) between A.G.P./Alliance Global Partners, as the sole placement agent (“A.G.P.”) (A.G.P. is also referred to herein as the “Placement Agent”), and Kintara Therapeutics, Inc., a Nevada corporation (the “Company”), the parties hereby agree that the Placement Agent shall serve as the placement agent for the Company, on a “reasonable best efforts” basis, in connection with the proposed placement (the “Placement”) of registered securities of the Company, consisting of: (i) shares of common stock, par value $0.001 per share (“Common Stock”), (ii) pre-funded warrants to purchase Common Stock (the “Pre-Funded Warrants”), and (iii) warrants to purchase Common Stock (the “Common Warrants” and collectively with the Pre-Funded Warrants, the “Warrants”). The Common Stock and Warrants actually placed by the Placement Agent are referred to herein as the “Placement Agent Securities.” The Placement Agent Securities and shares

Sample 1Sample 2Sample 3See All (31)
AGREEMENT AND PLAN OF MERGER by and among KINTARA THERAPEUTICS, INC., KAYAK MERGECO, INC. and TUHURA BIOSCIENCES, INC. Dated as of April 2, 2024
Merger Agreement • April 3rd, 2024 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Delaware

THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”), dated as of April 2, 2024, by and among Kintara Therapeutics, Inc., a Nevada corporation (which shall reincorporate as a Delaware corporation in connection with the consummation of the transactions contemplated hereby) (“Parent”), Kayak Mergeco, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and TuHURA Biosciences, Inc., a Delaware corporation (the “Company”).

Sample 1Sample 2Sample 3See All (31)
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • August 3rd, 2022 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • Nevada

REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of August 2, 2022, by and between KINTARA THERAPEUTICS, INC., a Nevada corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwise defined herein shall have the respective meanings set forth in the Purchase Agreement by and between the parties hereto, dated as of the date hereof (as amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”).

Sample 1Sample 2Sample 3See All (17)
4,095,000 SHARES of Common Stock, 2,655,000 PRE-FUNDED warrants (exercisable for 2,655,000 Shares) and 6,750,000 Warrants (exercisable for 6,750,000 Shares) of DELMAR PHARMACEUTICALS, INC. UNDERWRITING AGREEMENT
Underwriting Agreement • August 15th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

The undersigned, DelMar Pharmaceuticals, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Registration Statement as being subsidiaries or affiliates of DelMar Pharmaceuticals, Inc., the “Company”), hereby confirms its agreement (this “Agreement”) with the several underwriters (such underwriters, including the Representatives (as defined below), the “Underwriters” and each an “Underwriter”) named in Schedule I hereto for which Maxim Group LLC and Dawson James Securities, Inc. are acting as representatives to the several Underwriters (each a “Representative” and collectively, the “Representatives” and if there are no Underwriters other than the Representatives, references to multiple Underwriters shall be disregarded and the term Representatives as used herein shall have the same meaning as Underwriter) on the terms and conditions set forth herein.

Sample 1Sample 2Sample 3See All (15)
STRICTLY CONFIDENTIAL Kintara Therapeutics, Inc. 12707 High Bluff Dr., Suite 200 San Diego, CA 92130 Attn: Saiid Zarrabian, Chief Executive Officer Dear Mr. Zarrabian:
Exclusive Agency Agreement • September 28th, 2021 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York

This letter agreement (this “Agreement”) constitutes the agreement between Kintara Therapeutics, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive agent, advisor or underwriter in any offering (each, an “Offering”) of securities of the Company (the “Securities”) during the Term (as hereinafter defined) of this Agreement. The terms of each Offering and the Securities issued in connection therewith shall be mutually agreed upon by the Company and Wainwright and nothing herein implies that Wainwright would have the power or authority to bind the Company and nothing herein implies that the Company shall have an obligation to issue any Securities. It is understood that Wainwright’s assistance in an Offering will be subject to the satisfactory completion of such investigation and inquiry into the affairs of the Company as Wainwright deems appropriate under the circumstances and to the receipt of all internal approvals of Wainwrig

Sample 1Sample 2Sample 3See All (13)
INDEMNITY AGREEMENT
Indemnity Agreement • June 25th, 2018 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada

This Indemnity Agreement (this “Agreement”) dated as of ___________ _____, _____, is made by and between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and _________________ (“Indemnitee”).

Sample 1Sample 2Sample 3See All (12)
PLACEMENT AGENCY AGREEMENT
Placement Agency Agreement • August 21st, 2020 • Kintara Therapeutics, Inc. • Pharmaceutical preparations • New York

This Placement Agency Agreement (“Agreement”) sets forth the terms upon which Aegis Capital Corp., a New York corporation (“Aegis” or “Placement Agent”), a registered broker-dealer and member of the Financial Industry Regulatory Authority (“FINRA”), shall be engaged by DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”) to act as exclusive Placement Agent in connection with the private placement (the “Offering”) of shares (the “Shares”) of Series C Convertible Preferred Stock, par value $0.001 per share (the “Series C Preferred Stock”). The Offering will consist of a minimum of 10,000 Shares ($10 million) (“Minimum Offering Amount”) and up to a maximum of 20,000 Shares ($20 million) (“Maximum Offering Amount”) which shall be offered on a “reasonable efforts, all or none” basis as to the Minimum Offering Amount and a “reasonable efforts” basis for all amounts in excess of the Minimum Offering Amount. In the event the Offering is oversubscribed, the Company and Placement A

Sample 1Sample 2Sample 3See All (12)
REGISTRATION RIGHTS AGREEMENT
Registration Rights Agreement • July 2nd, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

This Registration Rights Agreement (this “Agreement”) is made and entered into effective as of , 2020 (the “Effective Date”) between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the persons who have executed the signature page(s) hereto (each, a “Purchaser” and collectively, the “Purchasers”).

Sample 1Sample 2Sample 3See All (12)
NONQUALIFIED STOCK OPTION GRANT AGREEMENT
Nonqualified Stock Option Grant Agreement • May 15th, 2018 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • Nevada

This Stock Option Grant Agreement (the “Grant Agreement”) is made and entered into effective on the Date of Grant set forth in Exhibit A (the “Date of Grant”) by and between DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the individual named in Exhibit A hereto (the “Optionee”).

Sample 1Sample 2Sample 3See All (11)
COMMON STOCK PURCHASE WARRANT DELMAR PHARMACEUTICALS, INC.
Warrant Agreement • August 15th, 2019 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date that is 180 days from the effective date (“Effective Date”) of the Registration Statement as defined below (the “Initial Exercise Date”) and on or prior to the close of business on [ ], 20221 (the “Termination Date”) but not thereafter, to subscribe for and purchase from DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to [_____] shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).

Sample 1Sample 2Sample 3See All (11)
Class B Warrants to Purchase One Share of Common Stock
Underwriting Agreement • May 12th, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New York

DelMar Pharmaceuticals, Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the several underwriters named on Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom Maxim Group LLC and Roth Capital Partners, LLC are acting as joint bookrunning managers (in such capacity, together the “Joint Bookrunners” and each, a “Joint Bookrunner”) and National Securities Corporation is acting as co-manager an aggregate of [____] shares (the “Firm Shares”) of common stock, par value $0.001 per share (the “Common Stock”), of the Company and [___] class A warrants (the “Class A Warrants”) and [____] class B warrants (the “Class B Warrant” and collectively, with the Class A Warrants, the “Firm Warrants”), each Class A Warrant entitles the holder to purchase one share of Common Stock at an exercise price of $[____] per share at any time prior to the expiration thereof on [____] and each Class B Warrant entitle

Sample 1Sample 2Sample 3See All (10)
AMENDED AND RESTATED EMPLOYMENT AGREEMENT
Employment Agreement • June 16th, 2020 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • New Jersey

This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Agreement”), dated as of March 1, 2018 (the “Effective Date”) is by and between ADGERO BIOPHARMACEUTICALS HOLDINGS, INC., a Delaware corporation (the “Company”) and John Liatos (the “Employee”).

Sample 1Sample 2Sample 3See All (7)
CONSULTING AGREEMENT
Consulting Agreement • April 10th, 2015 • DelMar Pharmaceuticals, Inc. • Pharmaceutical preparations • British Columbia

DEL MAR PHARMACEUTICALS (BC) LTD., with a registered address of Suite 720 – 999 West Broadway, Vancouver, British Columbia, Canada, V5Z 1K5;

Sample 1Sample 2Sample 3See All (7)
Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!